Fig. 1From: A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancerResidence time derived from serial positron emission tomography images (PET). Mean organ residence times (± standard deviation) for 64Cu-NOTA-TrastuzumabBack to article page